Huge Potential at SLXA

A few weeks ago, I wrote about two companies that are currently dominating the field of genetic analysis technology. Although I still think that AFFX and ILMN will continue to make great profits for investors, I am now thinking of switching to a new company called Solexa (SLXA). The company has a small market cap at $200 million, but is already attracting a lot of attention from the science community for its groundbreaking techniques of analyzing genetic material. The products that SLXA promises in the next few years will not only do a better job than the current methods, but will also be more efficient and cost-effective. Truly a disruptive technology. I believe the time to buy is now, given the type of growth AFFX and ILMN have experienced in this field. The company will report earnings today, and I expect some great guidance on the development of this new method. For those of us who missed the great growth story of ILMN, SLXA might just be the cure.